pericarditis medication - HEALTHIES
Taiwan News: Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis ARCALYST is the first-and-only FDA approved therapy for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older. ARCALYST is a weekly, ... Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis Nasdaq: Kiniksa Pharmaceuticals to Initiate Phase 2/3 Clinical Trial of KPL-387 for Recurrent Pericarditis in 2025, Discontinues Abiprubart Development Kiniksa Pharmaceuticals is set to begin a Phase 2/3 clinical trial for its drug KPL-387, aimed at treating recurrent pericarditis, in mid-2025.
Understanding the Context
The company has noted that data from the ongoing Phase 1 ... Kiniksa Pharmaceuticals to Initiate Phase 2/3 Clinical Trial of KPL-387 for Recurrent Pericarditis in 2025, Discontinues Abiprubart Development Credit: Getty Images A discussion on the new American Heart Association’s pericarditis initiative with Jimmy Kerrigan, MD. For the estimated 40,000 adults with recurrent pericarditis in the United ... Nasdaq: Kiniksa Pharmaceuticals Announces Phase 2/3 Trial Timeline for KPL-387 in Recurrent Pericarditis